Loading
Every dated change on the records linked to Brain metastases (secondary brain tumours), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
HER2+ metastatic breast cancer including brain metastases, with trastuzumab and capecitabine
5-year PFS 60% vs 8%, HR 0.
Cognitive failure hazard ratio 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Cognitive deterioration at 3 months 63.
Quality-adjusted life-years 46.
Brown and colleagues (JAMA): cognitive deterioration at three months in 63.5 percent with radiosurgery alone against 91.7 percent with added whole-brain radiotherapy; no survival difference.
A milestone in how this cancer is treated.